Sunitinib and bevacizumab for first-line treatment of metastatic renal cell carcinoma: a systematic review and indirect comparison of clinical effectiveness
Author:
Publisher
Springer Science and Business Media LLC
Subject
Cancer Research,Oncology
Link
http://www.nature.com/articles/6605167.pdf
Reference20 articles.
1. Ades AE (2003) A chain of evidence with mixed comparisons: models for multi-parameter synthesis and consistency of evidence. Stat Med 22: 2995–3016
2. Bajetta E, Ravaud A, Bracarda S, Negrier S, Szczylik C, Bellmunt J, Moore N, Pisa P, Escudier BJ (2008) Efficacy and safety of first-line bevacizumab (BEV) plus interferon-a2a (IFN) in patients (pts)>65 years with metastatic renal cell carcinoma (mRCC). J Clin Oncol 26: 5095
3. Bracarda S, Koralewski R, Pluzanska A, Ravaud A, Szczylik C, Chevreau C, Filipek M, Melichar B, Moore N, Escudierlo B (2007) Bevacizumab/interferon-alpha2a provides a progression-free survival benefit in all prespecified patient subgroups as first-line treatment of metastatic renal cell carcinoma (AVOREN). Ejc Supplements 5: 281–282
4. Coppin C, Porzsolt F, Awa A, Kumpf J, Coldman A, Wilt T (2005) Immunotherapy for advanced renal cell cancer. Cochrane Database Syst Rev (1): CD001425
5. Escudier B, Koralewski P, Pluzanska A, Ravaud A, Bracarda S, Szczylik C, Chevreau C, Filipek M, Melichar B, Moore N, on behalf of the AVOREN investigators (2007) A randomised, controlled, double blind phase III study (AVOREN) of bevacizumab/interferon-a2a vs placebo/interferon a2a as first line therapy in metastatic renal cell carcinoma. J Clin Oncol 25: 3
Cited by 50 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Genetic Deletion of Vascular Endothelial Growth Factor Receptor 2 in Endothelial Cells Leads to Immediate Disruption of Tumor Vessels and Aggravation of Hypoxia;The American Journal of Pathology;2022-02
2. Multimerin-2 orchestrates the cross-talk between endothelial cells and pericytes: A mechanism to maintain vascular stability;Matrix Biology Plus;2021-08
3. Comparative Efficacy and Safety of Dupilumab and Benralizumab in Patients with Inadequately Controlled Asthma: A Systematic Review;International Journal of Molecular Sciences;2020-01-30
4. Lupeol alters viability of SK-RC-45 (Renal cell carcinoma cell line) by modulating its mitochondrial dynamics;Heliyon;2019-08
5. Efficacy of targeted therapy for advanced renal cell carcinoma: A systematic review and meta-analysis of randomized controlled trials;International braz j urol;2018-04
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3